SEARCH

SEARCH BY CITATION

References

  • 1
    Vesely SK, Perdue JJ, Rizvi MA, Terrell DR, George JN. Management of adult patients with idiopathic thrombocytopenic purpura after failure of splenectomy. A systematic review. Ann Int Med 2004; 140: 11220.
  • 2
    Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic literature review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004; 104: 262334.
  • 3
    Portielje JEA, Westendorp RGJ, Kluin-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001; 97: 254954.
  • 4
    Neylon AJ, Saunders PWG, Howard MR, Proctor SJ, Taylor PRA. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol 2003; 122: 96674.
  • 5
    Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002; 346: 9951008.
  • 6
    Provan D, Newland A. Fifty years of idiopathic thrombocytopenic purpura (ITP): management of refractory ITP in adults. Br J Haematol 2002; 118: 93344.
  • 7
    British Committee for Standards in Haematology. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003; 120: 57496.
  • 8
    Cines DB, Bussel JB. How I treat idiopathic thrombocytopenic purpura (ITP). Blood 2005; 106: 224451.
  • 9
    Chong BH, Ho S-J. Autoimmune thrombocytopenia. J Thromb Haemost 2005; 3: 176372.
  • 10
    George JN, Raskob GE, Shah SR, Rizvi MA, Hamilton SA, Osborne S, Vondracek T. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Int Med 1998; 129: 88690.
  • 11
    Kojouri K, Perdue JJ, Medina PJ, George JN. Occult quinine-induced thrombocytopenia. Oklahoma State Med J 2000; 93: 51921.
  • 12
    Drachman JG. Inherited thrombocytopenia: when a low platelet count does not mean ITP. Blood 2004; 103: 3908.
  • 13
    Cortelazzo S, Finazzi G, Buelli M, Molteni A, Viero P, Barbui T. High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura. Blood 1991; 77: 313.
  • 14
    Vianelli N, Valdre L, Fiacchini M, De Vivo A, Gugliotta L, Catani L, Lemoli RM, Poli M, Tura S. Long-term follow-up of idiopathic thrombocytopenic purpura in 310 patients. Haematologia 2001; 86: 5049.
  • 15
    George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, Blanchette VS, Bussel JB, Cines DB, Kelton JG, Lichtin AE, McMillan R, Okerbloom JA, Regan DH, Warrier I. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996; 88: 340.
  • 16
    Cheng Y, Wong RS, Soo YO, Chui CH, Lau FY, Chan NP, Wong WS, Cheng G. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med 2003; 349: 8316.
  • 17
    George JN, Vesely SK. Immune thrombocytopenic purpura – let the treatment fit the patient. N Engl J Med 2003; 349: 9035.
  • 18
    Borst F, Kuening JJ, Van Hulsteijn H, Sinnige H, Vreugdenhil G. High-dose dexamethasone as a first- and second-line treatment of idiopathic thrombocytopenic purpura in adults. Ann Hematol 2004; 83: 7648.
  • 19
    Schilling RF. Estimating the risk for sepsis after splenectomy in hereditary spherocytosis. Ann Intern Med 1995; 122: 1878.
  • 20
    Robinette CD, Fraumeni JF. Splenectomy and subsequent mortality in veterans of the 1939–1945 war. Lancet 1977; ii: 1279.
  • 21
    Schilling RF. Spherocytosis, splenectomy, strokes, and heart attacks. Lancet 1997; 350: 16778.
  • 22
    Hoeper MM, Niedermeyer J, Hoffmeyer F, Flemming P, Fabel H. Pulmonary hypertension after splenectomy? Ann Int Med 1999; 130: 5069.
  • 23
    George JN, Raskob GE, Vesely SK, Moore Jr D, Lyons RM, Cobos E, Towell BL, Klug P, Guthrie TH. Initial management of immune thrombocytopenic purpura in adults: a randomized controlled trial comparing intermittant anti-D with routine care. Am J Hematol 2003; 74: 1619.
  • 24
    Bourgeois E, Caulier MT, Delarozee C, Brouillard M, Bauters F, Fenaux P. Long-term follow-up of chronic autoimmune thrombocytopenic purpura refractory to splenectomy: a prospective analysis. Br J Haematol 2003; 120: 107988.
  • 25
    McMillan R, Durette C. Long-term outcomes in adults with chronic ITP after splenectomy failure. Blood 2004; 104: 95660.
  • 26
    Guthrie TH, Brannan DP, Prisant LM. Idiopathic thrombocytopenic purpura in the older adult patient. Am J Med Sci 1988; 296: 1721.
  • 27
    Shashaty GG, Rath CE. Idiopathic thrombocytopenic purpura in the elderly. Am J Med Sci 1978; 276: 2637.
  • 28
    Van Staa TP, Leufkens HGM, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002; 13: 77787.
  • 29
    Imbach P, Kuhne T, Muller D, Berchtold W, Zimmerman S, Elalfy M, Buchanan GR. Childhood ITP: 12 months follow-up data from the prospective registry I of the intercontinental childhood ITP study group (ICIS). Pediatr Blood Cancer 2006; 46: 3516.
  • 30
    George JN, Woodson RD, Kiss JE, Kojouri K, Vesely SK. Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune-mediated disorders. J Clin Apheresis 2006; 21: 4956.
  • 31
    Bennett CM, Rogers ZR, Kinnamon DD, Bussel JB, Mahoney DH, Abshire TC, Sawaf H, Moore TB, Loh ML, Glader BE, McCarthy MC, Mueller BU, Olson TA, Lorenzana AN, Mentzer WC, Buchanan GR, Feldman HA, Neufeld EJ. Prospective phase I/II study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood 2006; 107: 263942.
  • 32
    Arnold DM, Dentali F, Meyer RM, Crowther MA, Sigouin C, Kelton JG. Rituximab for treatment of adults with ITP: a systematic review. Blood 2005; 106: 361a.
  • 33
    Verlin M, Laros RK, Penner JA. Treatment of refractory thrombocytopenic purpura with cyclophosphamide. Am J Hematol 1976; 1: 97104.
  • 34
    Pizzuto J, Ambriz R. Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: multicentric trial of the cooperative Latin American group on hemostasis and thrombosis. Blood 1984; 64: 117983.
  • 35
    Reiner A, Gernsheimer T, Slichter SJ. Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura. Blood 1995; 85: 3518.
  • 36
    Quiquandon I, Fenaux P, Caulier MT, Simon M, Walter MP, Bauters F. Re-evaluation of the role of azathioprine in the treatment of adult chronic idiopathic thrombocytopenic purpura: a report on 53 cases. Br J Haematol 1990; 74: 2238.
  • 37
    Figueroa M, Gehlsen J, Hammond D, Ondreyco S, Piro L, Pomeroy T, Williams F, McMillan R. Combination chemotherapy in refractory immune thrombocytopenic purpura. New Eng J Med 1993; 328: 12269.
  • 38
    McMillan R. Long-term outcomes after treatment for refractory immune thrombocytopenic purpura. New Eng J Med 2001; 344: 14023.
  • 39
    George JN, Kojouri K, Perdue JJ, Vesely SK. Management of patients with chronic, refractory idiopathic thrombocytopenic purpura. Semin Hematol 2000; 37: 110.
  • 40
    Huhn RD, Fogarty PF, Nakamura R, Read EJ, Leitman SF, Rick ME, Kimball J, Greene A, Hansmann K, Gratwohl A, Young N, Barrett AJ, Dunbar CE. High-dose cyclophosphamide with autologous lymphocyte-depleted peripheral blood stem cell (PBSC) support for treatment of refractory chronic autoimmune thrombocytopenia. Blood 2003; 101: 717.
  • 41
    Brodsky R, Petri M, Smith BD, Seifter EJ, Spivak JL, Styler M, Dang CV, Brodsky I, Jones RJ. Immunoablative high-dose cyclophosphamide without stem cell rescue for refractory, severe autoimmune disease. Ann Int Med 1998; 129: 10315.
  • 42
    Arrowsmith JB, Dreis M. Thrombocytopenia after treatment with Danazol. N Engl J Med 1986; 315: 585.
  • 43
    Rabinowe SN, Miller KB. Danazol-induced thrombocytopenia. Br J Haematol 1987; 65: 3834.
  • 44
    Fujimura K, Kuwana M, Kurata Y, Imamura M, Harada H, Sakamaki H, Teramura M, Koda K, Nomura S, Sugihara S, Shimomura T, Fujimoto TT, Oyashiki K, Ikeda Y. Is eradication therapy useful as the first line of treatment in Helicobacter pylori-positive idiopathic thrombocytopenic purpura? Analysis of 207 eradicated chronic ITP cases in Japan. Int J Hematol 2005; 81: 1628.
  • 45
    Michel M, Cooper N, Jean C, Frissora C, Bussel JB. Does Helicobacter pylori initiate or perpetuate immune thrombocytopenic purpura? Blood 2003; 103: 8906.
  • 46
    Jackson S, Beck PL, Pineo GF, Poon M-C. Helicobacter pylori eradication: novel therapy for immune thrombocytopenic purpura? A review of the literature. Am J Hematol 2005; 78: 14250.
  • 47
    Bussel JB, George JN, McMillan R, Erder MH, Nichol J, Lalla D. Initial results from an instrument developed to evaluate health-related quality-of-life in patients with immune thrombocytopenic purpura. Blood 2003; 102: 495a–6a.
  • 48
    Ballem PJ, Segal GM, Stratton JR, Gernsheimer T, Adamson JW, Slichter SJ. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenia purpura. Evidence for both impaired platelet production and increased platelet clearance. J Clin Invest 1987; 80: 3340.
  • 49
    Emmons RVB, Reid DM, Cohen RL, Meng G, Young NS, Dunbar CE, Shulman NR. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood 1996; 87: 406871.
  • 50
    Aledort L, Hayward CPM, Chen M-G, Nichol J, Bussel J. Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. Am J Hematol 2004; 76: 20513.
  • 51
    Chang M, Nakagawa PA, Williams SA, Schwartz MR, Imfeld KL, Buzby JS, Nugent DJ. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood 2003; 102: 88795.
  • 52
    McMillan R, Wang L, Tomer A, Nichol J, Pistillo J. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood 2004; 103: 13649.
  • 53
    Nomura S, Dan K, Hotta T, Fujimura K, Ikeda Y. Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenia purpura. Blood 2002; 100: 72830.
  • 54
    Bussel JB, George JN, Kuter DJ, Wasser JS, Aledort LM, Chen MG, Nichol JL. An open-label, dose-finding study evaluating the safety and platelet response of a novel thrombopoietic protein (AMG 531) in thrombocytopenic adult patients with immune thrombocytopenic purpura. Blood 2003; 102: 86a.
  • 55
    Kuter DJ, Bussel JB, Aledort L, George J, Lyons RM, Conklin GT, Lichtin AE, Nieva J, Kelly R, Chen C-F, Nichol JL. A phase 2 placebo controlled study evaluating the platelet count and safety of weekly dosing with a novel thrombopoietic protein (AMG531) in thrombocytopenic adult patients with immune thrombocytopenic purpura. Blood 2004; 104: 148a149a.
  • 56
    Bussel JB, Kuter DJ, George JN, Aledort L, Lichtin AE, Lyons RM, Nieva J, Wasser JS, Bourgeois E, Kappers-Klunne M, LeFrere F, Schipperus MR, Kelly R, Christal K, Chen C-F, Nichol JL. Long-term dosing of AMG 531 is effective and well tolerated in thrombocytopenic patients with immune thrombocytopenic purpura. Blood 2005; 106: 68a.
  • 57
    Broudy VC, Lin NL. AMG531 stimulates megakaryocytopoiesis in vitro by binding to Mpl. Cytokine 2004; 25: 5260.
  • 58
    Luengo JI, Duffy KJ, Shaw AN, Delorme E, Wiggall KJ, Giampa L, Liu N, Smith H, Tian SS, Miller SG, Keenan RM, Rosen K, Dillon SB, Lamb P, Erickson-Miller CL. Discovery of SB-497115, a small molecule thrombopoietin (TPO) receptor agonist for the treatment of thrombocytopenia. Blood 2004; 104: 795a.
  • 59
    Jenkins J, Nicholl R, Williams D, Baidoo C, Phillips K, Deng Y, Kitchen V, Erickson-Miller C. An oral, non-peptide, small molecule thrombopoietin receptor agonist increases platelet counts in healthy subjects. Blood 2004; 104: 797a.
  • 60
    GSK Announces Start Of Eltrombopag Phase III Worldwide Clinical Trial In Adults With Previously-Treated Idiopathic Thrombocytopenic Purpura [WWW document]. Medical News Today 2006. Available at: http://www.medicalnewstoday.com/medicalnews.php?newsid=37752 (accessed on 6 March 2006.)
  • 61
    Stepan DE, Sergis-Deavenport E, Kelly R, Christal J, Chen C-F, Nichol JL. Safety profile of AMG 531 in healthy volunteers and in thrombocytopenic patients with immune thrombocytopenic purpura. Blood 2005; 106: 361a.
  • 62
    Douglas VK, Tallman MS, Cripe LD, Peterson LC. Thrombopoietin administered during induction chemotherapy to patients with acute myeloid leukemia induces transient morphologic changes that may resemble chronic myeloproliferative disorders. Am J Clin Path 2002; 117: 84450.
  • 63
    Gardner FH, Helmer RE. Aminocaproic acid. Use in control of hemorrhage in patients with amegakaryocytic thrombocytopenia. JAMA 1980; 243: 357.
  • 64
    Bartholomew JR, Salgia R, Bell WR. Control of bleeding in patients with immune and nonimmune thrombocytopenia with aminocaproic acid. Arch Intern Med 1989; 149: 195961.
  • 65
    Abrahm J, Ellman L. Platelet transfusion in immune thrombocytopenic purpura. JAMA 1976; 236: 1847.
  • 66
    Carr JM, Kruskall MS, Kaye JA, Robinson SH. Efficacy of platelet transfusions in immune thrombocytopenia. Am J Med 1986; 80: 10514.
  • 67
    Gerotziafas GT, Zervas C, Gavrielidis G, Tokmaktsis A, Hatjiharissi E, Papaioannou M, Lazaridou A, Constantinou N, Samama MM, Christakis J. Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage. Am J Hematol 2002; 69: 21922.
  • 68
    Culic S. Recombinant factor VIIa for refractory haemorrhage in autoimmune idiopathic thrombocytopenic purpura. Br J Haematol 2003; 120: 90910.